Page last updated: 2024-12-05

oxybenzone

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Occurs in Manufacturing Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Oxybenzone, also known as benzophenone-3, is an organic compound that is widely used as a UV filter in sunscreen products. It acts by absorbing ultraviolet (UV) radiation, preventing it from reaching the skin and causing damage. Oxybenzone is synthesized through a multi-step process involving the reaction of benzophenone with a substituted phenol. Studies have indicated that oxybenzone can penetrate the skin and enter the bloodstream. It has been linked to potential endocrine disrupting effects, particularly concerning its ability to mimic estrogen. There are concerns about its potential to disrupt hormone balance, particularly in infants and young children. It is also being studied for its potential to contribute to coral bleaching. Due to these concerns, several countries and regions have restricted or banned the use of oxybenzone in sunscreen products.'

oxybenzone : A hydroxybenzophenone that is benzophenone which is substituted at the 2- and 4-positions of one of the benzene rings by hydroxy and methoxy groups respectively. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID4632
CHEMBL ID1625
CHEBI ID34283
SCHEMBL ID15551
MeSH IDM0046741

Synonyms (202)

Synonym
BIDD:ER0353
BRD-K59037100-001-05-5
uvinul m 40
4-methoxy-2-hydroxybenzophenone
usaf cy-9
wln: 1or cq dvr
advastab 45
uf 3
methanone, (2-hydroxy-4-methoxyphenyl)phenyl-
syntase 62
MOB ,
anuvex
uv 9
oxybenzon
uvistat 24
nsc7778
chimassorb 90
2-hydroxy-4-methoxybenzophenone
uvinul 9
cyasorb uv 9 light absorber
sunscreen uv-15
131-57-7
cyasorb uv 9
nsc-7778
spectra-sorb uv 9
benzophenone, 2-hydroxy-4-methoxy-
benzophenone-3
oxybenzone
smr000035344
DIVK1C_000184
KBIO1_000184
(2-hydroxy-4-methoxyphenyl)(phenyl)methanone
SPECTRUM_001049
BSPBIO_000674
OPREA1_174131
cas-131-57-7
NCGC00016394-01
BPBIO1_000742
BSPBIO_002155
D05309
IDI1_000184
SPECTRUM5_001337
NCGC00065306-03
inchi=1/c14h12o3/c1-17-11-7-8-12(13(15)9-11)14(16)10-5-3-2-4-6-10/h2-9,15h,1h
AB00052063
MLS001055487
nsc 7778
escalol 567
ccris 1078
nci-c60957
oxibenzonum
hsdb 4503
uvinul m40
ai3-23644
(2-hydroxy-4-methoxyphenyl)phenylmethanone
oxibenzona [inn-spanish]
oxybenzonum [inn-latin]
einecs 205-031-5
brn 1913145
ongrostab hmb
(2-hydroxy-4-methoxy-phenyl)-phenyl-methanone
2-hydroxy-4-methoxybenzophenone, 98%
DB01428
2-benzoyl-5-methoxyphenol ,
NCGC00065306-04
NCGC00065306-06
NCGC00065306-05
MLS000039797
KBIO3_001655
KBIO2_004097
KBIOGR_000906
KBIO2_006665
KBIOSS_001529
KBIO2_001529
SPECTRUM2_001008
SPECTRUM4_000463
PRESTWICK1_000887
SPBIO_002893
SPECTRUM3_000538
SPBIO_001135
PRESTWICK0_000887
NINDS_000184
SPECTRUM1500451
PRESTWICK3_000887
2-hydroxy-4-methoxy benzophenone
PRESTWICK2_000887
benzophenone 3
bp-3
eusolex 4360
2-hydroxy-4-methoxybenzone
STK057962
HMS2091L16
AC-11987
bdbm50253134
CHEBI:34283 ,
oxibenzona
oxybenzonum
HMS500J06
CHEMBL1625 ,
tinosorb b 3
uvinul 40
viosorb 110
H0266
HMS1570B16
HMS1920D16
(2-hydroxy-4-methoxyphenyl)-phenylmethanone
NCGC00016394-07
AKOS000120532
HMS2097B16
BBL003220
unii-95oos7ve0y
95oos7ve0y ,
oxybenzone [usan:usp:inn]
ec 205-031-5
dtxsid3022405 ,
tox21_302852
NCGC00256323-01
dtxcid002405
NCGC00259534-01
tox21_201985
pharmakon1600-01500451
nsc757260
nsc-757260
tox21_110418
S4691
CCG-40226
NCGC00016394-05
NCGC00016394-06
NCGC00016394-02
HMS2424P09
NCGC00016394-08
NCGC00016394-03
NCGC00016394-04
FT-0612546
AE-848/01549044
oxybenzone component of shade uvaguard
benzophenone-3 [inci]
oxybenzone [mi]
oxybenzone [inn]
shade uvaguard component oxybenzone
oxybenzone [hsdb]
oxybenzone [vandf]
oxybenzone [mart.]
oxybenzone [usan]
oxybenzone [who-dd]
benzophenone-3 [vandf]
oxybenzone [usp monograph]
oxybenzone [usp-rs]
oxybenzone [orange book]
EPITOPE ID:131795
HY-A0067
CS-3186
SCHEMBL15551
tox21_110418_1
NCGC00016394-10
(2-hydroxy-4-methoxyphenyl)(phenyl) methanone
2-hydroxy-4-methoxy-benzophenone
presun 15 (salt/mix)
neo heliopan bb
component of presun 29 (salt/mix)
component of presun 30 (salt/mix)
solaquin (salt/mix)
component of caraloe snow & sun lip balm (salt/mix)
component of presun 23 (salt/mix)
durascreen (salt/mix)
Q-200287
AB00052063_13
mfcd00008387
kahscreen bz-3
SR-01000610567-4
SR-01000610567-2
sr-01000610567
oxybenzone, analytical standard
oxybenzone, united states pharmacopeia (usp) reference standard
2-hydroxy-4-methoxybenzophenone, certified reference material, tracecert(r)
oxybenzone, pharmaceutical secondary standard; certified reference material
2-hydroxy-4-methoxybenzophenone 10 microg/ml in cyclohexane
SBI-0051470.P003
HMS3714B16
benzophenone 3;eusolex-4360;2-hydroxy-4-methoxybenzone
BCP25880
Q518114
AS-13616
BRD-K59037100-001-09-7
EN300-21523
F81513
A934242
Z104500700
sunscreen uv 15
sumisorb 110
oxybenzonum (inn-latin)
seesorb 101
aduvex 24
oxybenzone (usp monograph)
asl 24
oxybenzone (usan:usp:inn)
2-hydroxy-4-methoxybenzophenone,(2-hydroxy-4-methoxyphenyl)phenylmethanone
oxibenzona (inn-spanish)
oxybenzone (usp-rs)
bebak baby sun
oxybenzonum (latin)
oxybenzone (mart.)

Research Excerpts

Overview

Oxybenzone (BP-3) is an ultraviolet (UV) filter widely used in industries that is directly or indirectly released into the aquatic environment. Oxybenzone is a recognized endocrine disrupting chemical (EDC) and is small enough to pass through skin and placenta barriers.

ExcerptReferenceRelevance
"Oxybenzone is a widely used ultraviolet (UV) filter added to personal care products and other consumer goods to prevent UV damage, but potentially poses harm to humans, wildlife, and ecosystems."( Towards a paradigm shift in environmental health decision-making: a case study of oxybenzone.
Matouskova, K; Vandenberg, LN, 2022
)
1.67
"Oxybenzone (BP-3) is an ultraviolet (UV) filter widely used in industries that is directly or indirectly released into the aquatic environment. "( Benzophenone-3 causes oxidative stress in the brain and impairs aversive memory in adult zebrafish.
de Medeiros, SRB; de Souza, AM; Luchiari, AC; Moreira, ALP; Paiva, WS; Pereira, MCG; Rocha, HAO, 2023
)
2.35
"Oxybenzone is a ultraviolet (UV) absorber used in 70% of sunscreen products, is a recognized endocrine disrupting chemical (EDC) and is small enough to pass through skin and placenta barriers. "( Can oxybenzone cause Hirschsprung's disease?
DiNardo, JC; Downs, CA, 2019
)
2.51
"Oxybenzone is a common constituent of many commercially available sunscreens providing photoprotection from ultraviolet light incident on the skin. "( Probing the Ultrafast Energy Dissipation Mechanism of the Sunscreen Oxybenzone after UVA Irradiation.
Ashfold, MN; Baker, LA; Coulter, PM; Greenough, SE; Horbury, MD; Karsili, TN; Orr-Ewing, AJ; Roberts, GM; Stavros, VG, 2015
)
2.1
"Oxybenzone is an emerging contaminant of concern in marine environments—produced by swimmers and municipal, residential, and boat/ship wastewater discharges."( Toxicopathological Effects of the Sunscreen UV Filter, Oxybenzone (Benzophenone-3), on Coral Planulae and Cultured Primary Cells and Its Environmental Contamination in Hawaii and the U.S. Virgin Islands.
Bronstein, O; Cadenas, K; Ciner, FR; Downs, CA; Fauth, J; Jeger, R; Knutson, S; Kramarsky-Winter, E; Kushmaro, A; Lichtenfeld, Y; Loya, Y; Pennington, P; Segal, R; Woodley, CM, 2016
)
1.4
"Oxybenzone is an active ingredient found in sunscreen products that absorbs a broad spectrum of ultraviolet (UV) light, with absorbance peaking in the UVB region and extending into the UVA region. "( Rates of allergic sensitization and irritation to oxybenzone-containing sunscreen products: a quantitative meta-analysis of 64 exaggerated use studies.
Agin, PP; Hermansky, SJ; McCarthy, TJ; Ruble, K, 2008
)
2.04

Actions

ExcerptReferenceRelevance
"Oxybenzone was found to cause 4 cases of allergic contact dermatitis (with photoaggravation in 2), and 3 cases of photocontact dermatitis (13% of patients)."( Contact and photocontact allergy to oxybenzone.
Bensaïd, P; Khallouf, R; Lenique, P; Lorette, G; Machet, L; Muller, C; Vaillant, L, 1992
)
1.28

Toxicity

ExcerptReferenceRelevance
" This study suggests that BZ-3 is not toxic to rats when applied dermally at a dose of 100 mg/kg body wt."( Safety evaluation of benzophenone-3 after dermal administration in rats.
Abdel-Rahman, MS; Barat, SA; Okereke, CS, 1995
)
0.29
"Oxybenzone (OXB) is one of the most widely employed sunscreen ingredients, yet its allowed load is limited to a maximum of 6% reflecting the frequency with which adverse effects are reported."( Reducing adverse effects from UV sunscreens by zeolite encapsulation: comparison of oxybenzone in solution and in zeolites.
Chrétien, MN; Heafey, E; Scaiano, JC,
)
1.8
"Sunscreens are widely utilized due to the adverse effects of ultraviolet (UV) radiation on human health."( Altered UV absorbance and cytotoxicity of chlorinated sunscreen agents.
Kennedy, S; Purser, GH; Sheaff, RJ; Sherwood, VF; Zhang, H, 2012
)
0.38
" The results indicated that most TPs may be less toxic than their parent chemicals, but some may be more toxic, and that intestinal toxicity of TPs may be more obvious than blood toxicity."( A novel two-dimensional liquid-chromatography method for online prediction of the toxicity of transformation products of benzophenones after water chlorination.
Li, J; Ma, LY; Shi, ZG; Xu, L, 2015
)
0.42
"Benzophenone-3 (BP-3) is a popular ultraviolet absorbing chemical and has an adverse impact on aquatic ecosystems and human health."( Degradation of benzophenone-3 by the ozonation in aqueous solution: kinetics, intermediates and toxicity.
Guo, Y; Lin, Q; Qi, F; Xu, B, 2016
)
0.43
" In particular, toxic products might be produced during reaction with disinfectants during the disinfection process."( Chlorination of oxybenzone: Kinetics, transformation, disinfection byproducts formation, and genotoxicity changes.
Wang, X; Xie, YF; Yang, H; Zhang, S, 2016
)
0.78
" Research data on the toxic effects of benzophenone-3, especially on aquatic organisms are scarce, so further investigations were carried out regarding its cytotoxic and teratogenic effects on bacteria and zebrafish (Danio rerio) embryos, respectively."( Hormonal activity, cytotoxicity and developmental toxicity of UV filters.
Balázs, A; Csenki, Z; Kovács, R; Krifaton, C; Kriszt, B; Orosz, I; Szoboszlay, S; Urbányi, B, 2016
)
0.43
" We first determined a range of nominal toxic concentration of each ingredient or substance using Daphnia magna, and then for the subsequent organismal level phenotypic assessment, chose the wild-type zebrafish embryos."( Sequential assessment via daphnia and zebrafish for systematic toxicity screening of heterogeneous substances.
Jang, GH; Kang, BJ; Kim, YJ; Lee, KH; Park, CB, 2016
)
0.43
" Although BP-3 protects the human skin and hair from damage caused by excessive UV radiation, it is reported to exhibit toxic effects in human."( Cytotoxicity of benzophenone-3, an organic ultraviolet filter, caused by increased intracellular Zn
Abe, S; Bekki, Y; Hamada, S; Hiraishi, R; Kamemura, N; Kishimoto, K; Utsunomiya, H, 2019
)
0.51
"Environmental contamination by benzophenone-3 has gained attention because of its frequent occurrence and adverse environmental impact."( Toxicity of benzophenone-3 and its biodegradation in a freshwater microalga Scenedesmus obliquus.
Govindwar, SP; Jeon, BH; Kurade, MB; Lee, SH; Oh, SE; Patil, SM; Ru, S; Xiong, JQ, 2020
)
0.56
" Few studies explore its adverse effects at environmental relevant concentrations."( Environmental relevant concentrations of benzophenone-3 induced developmental neurotoxicity in zebrafish.
Bai, C; Chen, Y; Dong, H; Dong, Q; Huang, C; Li, L; Liu, Y; Pan, W; Shi, Q; Tanguay, R; Tao, J; Xu, H; Zhou, H, 2020
)
0.56
"Plastic additives may accelerate adverse effects of microplastics (MPs)."( Role of benzophenone-3 additive in chronic toxicity of polyethylene microplastic fragments to Daphnia magna.
An, D; Jung, J; Na, J; Song, J, 2021
)
0.62
" Mussels exposed to MPs on a daily basis demonstrated a cumulative toxic effect."( Size-dominated biotoxicity of microplastics laden with benzophenone-3 and ciprofloxacin: Enhanced integrated biomarker evaluation on mussels.
Gin, KY; He, Y; Jong, MC; Li, J, 2023
)
0.91

Compound-Compound Interactions

ExcerptReferenceRelevance
"A method has been developed for the separation and determination of three hydrophobic benzophenones: 2,4-dihydroxybenzophenone (BP-1), 2,2'4,4'-tetrahydroxybenzophenone (BP-2), and 2-hydroxy-4-methoxybenzophenone (BP-3) in sunscreen by micellar electrokinetic capillary chromatography (MEKC) combined with cloud point extraction (CPE)."( Cloud point extraction combined with micellar electrokinetic capillary chromatography determination of benzophenones in cosmetic matrix.
Jiang, YY; Liu, JF; Wu, YW; Xiong, K, 2008
)
0.35
"To evaluate the beneficial influence of melatonin in topical sunscreen emulsions combined with three common ultraviolet filters."( In vivo and in vitro evaluation of the use of a newly developed melatonin loaded emulsion combined with UV filters as a protective agent against skin irradiation.
Campmany, AC; Martínez, AR; Naveros, BC; Ramírez, ML; Sierra, AF, 2013
)
0.39
" Melatonin permeation was higher from the emulsion containing melatonin combined with a mixture of three ultraviolet filters (MMIX) formulation."( In vivo and in vitro evaluation of the use of a newly developed melatonin loaded emulsion combined with UV filters as a protective agent against skin irradiation.
Campmany, AC; Martínez, AR; Naveros, BC; Ramírez, ML; Sierra, AF, 2013
)
0.39

Bioavailability

ExcerptReferenceRelevance
" Bioavailability of the chemical absorbed through the skin is different from that seen through the oral route."( Disposition of benzophenone-3 after dermal administration in male rats.
Abdel-Rhaman, MS; Friedman, MA; Okereke, CS, 1994
)
0.29
"The aim of the present study was to objectively quantify and predict bioavailability of three sunscreen agents (i."( Measurement, analysis and prediction of topical UV filter bioavailability.
Gabard, B; Gilbert, E; Haftek, M; Maibach, HI; Pirot, F; Roussel, L; Salmon, D; Serre, C, 2015
)
0.42
" The aim of this work was to compare percutaneous absorption and cutaneous bioavailability of BP-3 loaded into solid lipid nanoparticles (SLN), nanostructured lipid carriers (NLC), nanostructured polymeric lipid carriers (NPLC) and nanocapsules (NC)."( Percutaneous absorption of benzophenone-3 loaded lipid nanoparticles and polymeric nanocapsules: A comparative study.
Falson, F; Gilbert, E; Haftek, M; Kirilov, P; Pirot, F; Roussel, L; Salmon, D; Sandouk, R; Serre, C, 2016
)
0.43
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51
" However, whether this specificity is due to the lack of degradation genes, cellular transport or low bioavailability of the other UV filters remained unclear."( Efficient degradation of the organic UV filter benzophenone-3 by Sphingomonas wittichii strain BP14P isolated from WWTP sludge.
Fagervold, SK; Lebaron, P; Rodrigues, AMS; Rohée, C; Stien, D, 2021
)
0.62
"Aquatic natural colloids are closely related to the environmental behavior of pollutants, which may affect their bioavailability in aquatic organisms."( Natural colloids at environmentally relevant concentrations affect the absorption and removal of benzophenone-3 in zebrafish.
Ling, X; Liu, J; Lu, G; Sun, Y; Wang, Y; Xue, Q; Yan, Z; Zhang, P, 2022
)
0.72

Dosage Studied

ExcerptRelevanceReference
" Additional high dosage and control mice were also included and euthanized at interim time points to characterize the time course of any effects."( Assessment of the reproductive toxic potential of dermally applied 2-hydroxy-4-methoxybenzophenone to male B6C3F1 mice.
Carlton, BD; Chudkowski, M; Daston, GP; Davis, RA; Gettings, SD; Hoberman, AM; Kraus, AL; Luke, CF; Oellette, RE; Re, TA, 1993
)
0.29
" The two key implications from this work are (i) a recognition of the danger in the potential extrapolation of infinite dosing to in use situations, and (ii) to recognize that thicker formulations may sometimes enhance the penetration of other topical agents when applied "in use"."( Can increasing the viscosity of formulations be used to reduce the human skin penetration of the sunscreen oxybenzone?
Benson, HA; Cross, SE; Jiang, R; Roberts, MS, 2001
)
0.52
"87%) in the dosing range of concentrations."( Simultaneous determination of some phthalate metabolites, parabens and benzophenone-3 in urine by ultra high pressure liquid chromatography tandem mass spectrometry.
Charlier, C; Dewalque, L; Dubois, N; Pirard, C, 2014
)
0.4
"Desonide is a topical corticoid used in the treatment of skin diseases and is marketed in different pharmaceutical dosage forms."( Investigation of the stabilizing effects of antioxidants and benzophenone-3 on desonide photostability.
Bueno Rolim, CM; de Bona da Silva, C; Horn Adams, AI; Rosa, P; Snovarski Salla, AP, 2014
)
0.4
" bi-hourly) was not observed to affect the removal efficiency of the cited conventional water quality parameters, significantly lower removal efficiencies were found for tonalide and bisphenol A for the VF wetland that received bi-hourly dosing (VS2p) (higher volume per pulse), probably due to the more reducing conditions observed in that system."( Emerging organic contaminants in vertical subsurface flow constructed wetlands: influence of media size, loading frequency and use of active aeration.
Avila, C; Bayona, JM; García, J; Headley, T; Kassa, K; Mueller, RA; Nivala, J; Olsson, L, 2014
)
0.4
"To determine the effects of maternal and lactational exposure to HMB on development and reproductive organs of offspring, time-mated female Harlan Sprague-Dawley rats were dosed with 0, 1000, 3000, 10,000, 25,000, or 50,000 ppm HMB (seven to eight per group) added to chow from gestation day 6 until weaning on postnatal day (PND) 23."( Effects of maternal and lactational exposure to 2-hydroxy-4-methoxybenzone on development and reproductive organs in male and female rat offspring.
Bryant, MS; Chang, CW; Foster, PM; Hansen, DK; Harrouk, W; Inselman, AL; McIntyre, BS; Nakamura, N; Patton, RE; Sephr, E; Trbojevich, RA; Voris, KL; White, GA, 2015
)
0.66
" The results showed that BP-3 degradation rate constant decreased with increasing initial BP-3 concentration, while increased with increasing H2O2 dosage and UV intensity."( [Degradation of Organic Sunscreens 2-hydroxy-4-methoxybenzophenone by UV/ H2O2 Process: Kinetics and Factors].
Du, ED; Feng, XX; Guo, YQ; Li, HJ; Liu, X; Zhou, F, 2015
)
0.42
" What's more, we discovered dose-response relationship between RET expression and BP-3 exposure dose, and miR-218 and some other genes involved in SLIT2/ROBO1-miR-218-RET/PLAG1 pathway were also related to BP-3 exposure."( The relationship between prenatal exposure to BP-3 and Hirschsprung's disease.
Cai, P; Chen, M; Huo, W; Li, H; Tang, J; Tang, W; Xia, Y; Xu, C; Zhu, D, 2016
)
0.43
" riparius fecundity was not affected by BP3 exposure, but a strong dose-response relationship was observed for fertility with none of the egg ropes hatching at 8mg BP3/kg."( Two-generational effects of Benzophenone-3 on the aquatic midge Chironomus riparius.
Campos, D; Grabicová, K; Loureiro, S; Pestana, JLT; Silva, ARR; Soares, AMVM; Staňová, AV, 2019
)
0.51
" In this study, the ecotoxicity of benzophenone-3 on Scenedesmus obliquus was assessed through dose-response test, risk quotient evaluation, and changes of microalgal biochemical characteristics and gene expression."( Toxicity of benzophenone-3 and its biodegradation in a freshwater microalga Scenedesmus obliquus.
Govindwar, SP; Jeon, BH; Kurade, MB; Lee, SH; Oh, SE; Patil, SM; Ru, S; Xiong, JQ, 2020
)
0.56
" The goal of this study was to assess the efficacy of coagulation/flocculation/sedimentation (C/F/S), adsorption onto two types of powdered activated carbon (PAC)/sedimentation (PAC/S) and the combination of these two processes in different dosing sequences (PAC/C/F/S) and with/without ultrafiltration (powdered activated carbon/ultrafiltration-PAC/UF, coagulation/UF-CoA/UF) for the removal of selected micropollutants from river water."( Fate of Benzophenone, Benzophenone-3 and Caffeine in Lab-Scale Direct River Water Treatment by Hybrid Processes.
Bogunović, M; Ivančev-Tumbas, I; Marjanović, T, 2021
)
0.62
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Occurs in Manufacturing (3 Product(s))

Product Categories

Product CategoryProducts
Beauty & Personal Care2
Baby & Kids Products1

Products

ProductBrandCategoryCompounds Matched from IngredientsDate Retrieved
Cococare Vitamin E Antioxidant Gel -- 8.5 fl ozCococareBeauty & Personal Carevitamin E acetate, chamomile, beta-carotene, glycerin, henna, benzophenone-3, propylene glycol, retinyl palmitate, sodium benzoate, triethanolamine2024-11-29 10:47:42
Fairy Tales Lice Prevention Rosemary Repel Creme Conditioner -- 32 fl ozFairy TalesBaby & Kids Productscaprylyl glycol, citric acid, cetrimonium bromide, cetyl alcohol, citric acid, citronella, glycerin, benzophenone-3, phenoxyethanol, sorbic acid, stearyl alcohol, triethanolamine2024-11-29 10:47:42
Monoi Tiki Tahiti Coconut Suntan Oil SPF 6 -- 4 fl ozMonoiBeauty & Personal Caretocopherol acetate, vitamin E, vitamin E, oxybenzone2024-11-29 10:47:42

Roles (5)

RoleDescription
dermatologic drugA drug used to treat or prevent skin disorders or for the routine care of skin.
protective agentSynthetic or natural substance which is given to prevent a disease or disorder or are used in the process of treating a disease or injury due to a poisonous agent.
ultraviolet filterA photochemical role realized in the absorption of ultraviolet light, for example to protect skin cells from damage.
xenobioticA xenobiotic (Greek, xenos "foreign"; bios "life") is a compound that is foreign to a living organism. Principal xenobiotics include: drugs, carcinogens and various compounds that have been introduced into the environment by artificial means.
environmental contaminantAny minor or unwanted substance introduced into the environment that can have undesired effects.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (2)

ClassDescription
hydroxybenzophenoneAny benzophenone into which is substituted one or more hydroxy groups.
monomethoxybenzeneCompounds containing a benzene skeleton substituted with one methoxy group.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (47)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
LuciferasePhotinus pyralis (common eastern firefly)Potency27.03150.007215.758889.3584AID1224835; AID588342; AID624030
RAR-related orphan receptor gammaMus musculus (house mouse)Potency15.74960.006038.004119,952.5996AID1159521; AID1159523
SMAD family member 2Homo sapiens (human)Potency27.53910.173734.304761.8120AID1346859
ATAD5 protein, partialHomo sapiens (human)Potency17.35820.004110.890331.5287AID504466; AID504467
USP1 protein, partialHomo sapiens (human)Potency63.09570.031637.5844354.8130AID504865
SMAD family member 3Homo sapiens (human)Potency27.53910.173734.304761.8120AID1346859
TDP1 proteinHomo sapiens (human)Potency30.05340.000811.382244.6684AID686978; AID686979
GLI family zinc finger 3Homo sapiens (human)Potency1.92990.000714.592883.7951AID1259369
AR proteinHomo sapiens (human)Potency23.12840.000221.22318,912.5098AID1259243; AID1259247; AID743036; AID743042; AID743063
Smad3Homo sapiens (human)Potency3.98110.00527.809829.0929AID588855
aldehyde dehydrogenase 1 family, member A1Homo sapiens (human)Potency34.35210.011212.4002100.0000AID1030
nuclear receptor subfamily 1, group I, member 3Homo sapiens (human)Potency31.08290.001022.650876.6163AID1224838; AID1224839; AID1224893
progesterone receptorHomo sapiens (human)Potency45.63530.000417.946075.1148AID1346795
retinoic acid nuclear receptor alpha variant 1Homo sapiens (human)Potency23.65670.003041.611522,387.1992AID1159552; AID1159553; AID1159555
retinoid X nuclear receptor alphaHomo sapiens (human)Potency29.39690.000817.505159.3239AID588544
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency26.77620.001530.607315,848.9004AID1224841; AID1224842; AID1224848; AID1224849; AID1259401; AID1259403
pregnane X nuclear receptorHomo sapiens (human)Potency48.57970.005428.02631,258.9301AID1346982; AID720659
estrogen nuclear receptor alphaHomo sapiens (human)Potency29.89560.000229.305416,493.5996AID1259244; AID1259248; AID588514; AID743075; AID743077; AID743078; AID743079; AID743080; AID743091
GVesicular stomatitis virusPotency38.90180.01238.964839.8107AID1645842
bromodomain adjacent to zinc finger domain 2BHomo sapiens (human)Potency79.43280.707936.904389.1251AID504333
P53Homo sapiens (human)Potency35.48130.07319.685831.6228AID504706
peroxisome proliferator-activated receptor deltaHomo sapiens (human)Potency11.88230.001024.504861.6448AID743215
aryl hydrocarbon receptorHomo sapiens (human)Potency35.07600.000723.06741,258.9301AID743085; AID743122
cytochrome P450, family 19, subfamily A, polypeptide 1, isoform CRA_aHomo sapiens (human)Potency10.45200.001723.839378.1014AID743083
thyroid stimulating hormone receptorHomo sapiens (human)Potency30.34580.001628.015177.1139AID1224843; AID1224895; AID1259385
activating transcription factor 6Homo sapiens (human)Potency0.17380.143427.612159.8106AID1159516
cytochrome P450 2D6 isoform 1Homo sapiens (human)Potency12.58930.00207.533739.8107AID891
cytochrome P450 2C19 precursorHomo sapiens (human)Potency0.39810.00255.840031.6228AID899
15-hydroxyprostaglandin dehydrogenase [NAD(+)] isoform 1Homo sapiens (human)Potency12.96230.001815.663839.8107AID894
chromobox protein homolog 1Homo sapiens (human)Potency89.12510.006026.168889.1251AID540317
potassium voltage-gated channel subfamily H member 2 isoform dHomo sapiens (human)Potency30.30010.01789.637444.6684AID588834
histone deacetylase 9 isoform 3Homo sapiens (human)Potency47.95390.037617.082361.1927AID1259364; AID1259388
huntingtin isoform 2Homo sapiens (human)Potency11.22020.000618.41981,122.0200AID1688
mitogen-activated protein kinase 1Homo sapiens (human)Potency31.62280.039816.784239.8107AID995
nuclear factor erythroid 2-related factor 2 isoform 1Homo sapiens (human)Potency51.78810.000627.21521,122.0200AID651741; AID720636
DNA polymerase kappa isoform 1Homo sapiens (human)Potency15.84890.031622.3146100.0000AID588579
lamin isoform A-delta10Homo sapiens (human)Potency35.48130.891312.067628.1838AID1487
Voltage-dependent calcium channel gamma-2 subunitMus musculus (house mouse)Potency26.92500.001557.789015,848.9004AID1259244
Interferon betaHomo sapiens (human)Potency38.90180.00339.158239.8107AID1645842
HLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)Potency38.90180.01238.964839.8107AID1645842
Glutamate receptor 2Rattus norvegicus (Norway rat)Potency26.92500.001551.739315,848.9004AID1259244
Nuclear receptor ROR-gammaHomo sapiens (human)Potency37.57800.026622.448266.8242AID651802
Guanine nucleotide-binding protein GHomo sapiens (human)Potency1.00001.995325.532750.1187AID624287
TAR DNA-binding protein 43Homo sapiens (human)Potency3.54811.778316.208135.4813AID652104
Inositol hexakisphosphate kinase 1Homo sapiens (human)Potency38.90180.01238.964839.8107AID1645842
cytochrome P450 2C9, partialHomo sapiens (human)Potency38.90180.01238.964839.8107AID1645842
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Hormone-sensitive lipaseRattus norvegicus (Norway rat)IC50 (µMol)3.25000.37001.27003.2500AID390722
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (81)

Processvia Protein(s)Taxonomy
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell activation involved in immune responseInterferon betaHomo sapiens (human)
cell surface receptor signaling pathwayInterferon betaHomo sapiens (human)
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to virusInterferon betaHomo sapiens (human)
positive regulation of autophagyInterferon betaHomo sapiens (human)
cytokine-mediated signaling pathwayInterferon betaHomo sapiens (human)
natural killer cell activationInterferon betaHomo sapiens (human)
positive regulation of peptidyl-serine phosphorylation of STAT proteinInterferon betaHomo sapiens (human)
cellular response to interferon-betaInterferon betaHomo sapiens (human)
B cell proliferationInterferon betaHomo sapiens (human)
negative regulation of viral genome replicationInterferon betaHomo sapiens (human)
innate immune responseInterferon betaHomo sapiens (human)
positive regulation of innate immune responseInterferon betaHomo sapiens (human)
regulation of MHC class I biosynthetic processInterferon betaHomo sapiens (human)
negative regulation of T cell differentiationInterferon betaHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIInterferon betaHomo sapiens (human)
defense response to virusInterferon betaHomo sapiens (human)
type I interferon-mediated signaling pathwayInterferon betaHomo sapiens (human)
neuron cellular homeostasisInterferon betaHomo sapiens (human)
cellular response to exogenous dsRNAInterferon betaHomo sapiens (human)
cellular response to virusInterferon betaHomo sapiens (human)
negative regulation of Lewy body formationInterferon betaHomo sapiens (human)
negative regulation of T-helper 2 cell cytokine productionInterferon betaHomo sapiens (human)
positive regulation of apoptotic signaling pathwayInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell differentiationInterferon betaHomo sapiens (human)
natural killer cell activation involved in immune responseInterferon betaHomo sapiens (human)
adaptive immune responseInterferon betaHomo sapiens (human)
T cell activation involved in immune responseInterferon betaHomo sapiens (human)
humoral immune responseInterferon betaHomo sapiens (human)
positive regulation of T cell mediated cytotoxicityHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
adaptive immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
antigen processing and presentation of endogenous peptide antigen via MHC class I via ER pathway, TAP-independentHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of T cell anergyHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
defense responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
detection of bacteriumHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of interleukin-12 productionHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of interleukin-6 productionHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protection from natural killer cell mediated cytotoxicityHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
innate immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of dendritic cell differentiationHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
antigen processing and presentation of endogenous peptide antigen via MHC class IbHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
negative regulation of transcription by RNA polymerase IINuclear receptor ROR-gammaHomo sapiens (human)
xenobiotic metabolic processNuclear receptor ROR-gammaHomo sapiens (human)
regulation of glucose metabolic processNuclear receptor ROR-gammaHomo sapiens (human)
regulation of steroid metabolic processNuclear receptor ROR-gammaHomo sapiens (human)
intracellular receptor signaling pathwayNuclear receptor ROR-gammaHomo sapiens (human)
circadian regulation of gene expressionNuclear receptor ROR-gammaHomo sapiens (human)
cellular response to sterolNuclear receptor ROR-gammaHomo sapiens (human)
positive regulation of circadian rhythmNuclear receptor ROR-gammaHomo sapiens (human)
regulation of fat cell differentiationNuclear receptor ROR-gammaHomo sapiens (human)
positive regulation of DNA-templated transcriptionNuclear receptor ROR-gammaHomo sapiens (human)
adipose tissue developmentNuclear receptor ROR-gammaHomo sapiens (human)
T-helper 17 cell differentiationNuclear receptor ROR-gammaHomo sapiens (human)
regulation of transcription by RNA polymerase IINuclear receptor ROR-gammaHomo sapiens (human)
negative regulation of inflammatory response to antigenic stimulusGuanine nucleotide-binding protein GHomo sapiens (human)
renal water homeostasisGuanine nucleotide-binding protein GHomo sapiens (human)
G protein-coupled receptor signaling pathwayGuanine nucleotide-binding protein GHomo sapiens (human)
regulation of insulin secretionGuanine nucleotide-binding protein GHomo sapiens (human)
cellular response to glucagon stimulusGuanine nucleotide-binding protein GHomo sapiens (human)
negative regulation of protein phosphorylationTAR DNA-binding protein 43Homo sapiens (human)
mRNA processingTAR DNA-binding protein 43Homo sapiens (human)
RNA splicingTAR DNA-binding protein 43Homo sapiens (human)
negative regulation of gene expressionTAR DNA-binding protein 43Homo sapiens (human)
regulation of protein stabilityTAR DNA-binding protein 43Homo sapiens (human)
positive regulation of insulin secretionTAR DNA-binding protein 43Homo sapiens (human)
response to endoplasmic reticulum stressTAR DNA-binding protein 43Homo sapiens (human)
positive regulation of protein import into nucleusTAR DNA-binding protein 43Homo sapiens (human)
regulation of circadian rhythmTAR DNA-binding protein 43Homo sapiens (human)
regulation of apoptotic processTAR DNA-binding protein 43Homo sapiens (human)
negative regulation by host of viral transcriptionTAR DNA-binding protein 43Homo sapiens (human)
rhythmic processTAR DNA-binding protein 43Homo sapiens (human)
regulation of cell cycleTAR DNA-binding protein 43Homo sapiens (human)
3'-UTR-mediated mRNA destabilizationTAR DNA-binding protein 43Homo sapiens (human)
3'-UTR-mediated mRNA stabilizationTAR DNA-binding protein 43Homo sapiens (human)
nuclear inner membrane organizationTAR DNA-binding protein 43Homo sapiens (human)
amyloid fibril formationTAR DNA-binding protein 43Homo sapiens (human)
regulation of gene expressionTAR DNA-binding protein 43Homo sapiens (human)
inositol phosphate metabolic processInositol hexakisphosphate kinase 1Homo sapiens (human)
phosphatidylinositol phosphate biosynthetic processInositol hexakisphosphate kinase 1Homo sapiens (human)
negative regulation of cold-induced thermogenesisInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol phosphate biosynthetic processInositol hexakisphosphate kinase 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (37)

Processvia Protein(s)Taxonomy
cytokine activityInterferon betaHomo sapiens (human)
cytokine receptor bindingInterferon betaHomo sapiens (human)
type I interferon receptor bindingInterferon betaHomo sapiens (human)
protein bindingInterferon betaHomo sapiens (human)
chloramphenicol O-acetyltransferase activityInterferon betaHomo sapiens (human)
TAP bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
signaling receptor bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protein bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
peptide antigen bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
TAP bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protein-folding chaperone bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingNuclear receptor ROR-gammaHomo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificNuclear receptor ROR-gammaHomo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specificNuclear receptor ROR-gammaHomo sapiens (human)
DNA-binding transcription factor activityNuclear receptor ROR-gammaHomo sapiens (human)
protein bindingNuclear receptor ROR-gammaHomo sapiens (human)
oxysterol bindingNuclear receptor ROR-gammaHomo sapiens (human)
zinc ion bindingNuclear receptor ROR-gammaHomo sapiens (human)
ligand-activated transcription factor activityNuclear receptor ROR-gammaHomo sapiens (human)
sequence-specific double-stranded DNA bindingNuclear receptor ROR-gammaHomo sapiens (human)
nuclear receptor activityNuclear receptor ROR-gammaHomo sapiens (human)
G protein activityGuanine nucleotide-binding protein GHomo sapiens (human)
adenylate cyclase activator activityGuanine nucleotide-binding protein GHomo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingTAR DNA-binding protein 43Homo sapiens (human)
DNA bindingTAR DNA-binding protein 43Homo sapiens (human)
double-stranded DNA bindingTAR DNA-binding protein 43Homo sapiens (human)
RNA bindingTAR DNA-binding protein 43Homo sapiens (human)
mRNA 3'-UTR bindingTAR DNA-binding protein 43Homo sapiens (human)
protein bindingTAR DNA-binding protein 43Homo sapiens (human)
lipid bindingTAR DNA-binding protein 43Homo sapiens (human)
identical protein bindingTAR DNA-binding protein 43Homo sapiens (human)
pre-mRNA intronic bindingTAR DNA-binding protein 43Homo sapiens (human)
molecular condensate scaffold activityTAR DNA-binding protein 43Homo sapiens (human)
inositol-1,3,4,5,6-pentakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol heptakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 5-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
protein bindingInositol hexakisphosphate kinase 1Homo sapiens (human)
ATP bindingInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 1-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 3-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol 5-diphosphate pentakisphosphate 5-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol diphosphate tetrakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (31)

Processvia Protein(s)Taxonomy
extracellular spaceInterferon betaHomo sapiens (human)
extracellular regionInterferon betaHomo sapiens (human)
Golgi membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
endoplasmic reticulumHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
Golgi apparatusHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
plasma membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
cell surfaceHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
ER to Golgi transport vesicle membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
secretory granule membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
phagocytic vesicle membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
early endosome membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
recycling endosome membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
extracellular exosomeHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
lumenal side of endoplasmic reticulum membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
MHC class I protein complexHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
extracellular spaceHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
external side of plasma membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
lipid dropletHormone-sensitive lipaseRattus norvegicus (Norway rat)
cytosolHormone-sensitive lipaseRattus norvegicus (Norway rat)
plasma membraneGlutamate receptor 2Rattus norvegicus (Norway rat)
nucleusNuclear receptor ROR-gammaHomo sapiens (human)
nucleoplasmNuclear receptor ROR-gammaHomo sapiens (human)
nuclear bodyNuclear receptor ROR-gammaHomo sapiens (human)
chromatinNuclear receptor ROR-gammaHomo sapiens (human)
nucleusNuclear receptor ROR-gammaHomo sapiens (human)
plasma membraneGuanine nucleotide-binding protein GHomo sapiens (human)
intracellular non-membrane-bounded organelleTAR DNA-binding protein 43Homo sapiens (human)
nucleusTAR DNA-binding protein 43Homo sapiens (human)
nucleoplasmTAR DNA-binding protein 43Homo sapiens (human)
perichromatin fibrilsTAR DNA-binding protein 43Homo sapiens (human)
mitochondrionTAR DNA-binding protein 43Homo sapiens (human)
cytoplasmic stress granuleTAR DNA-binding protein 43Homo sapiens (human)
nuclear speckTAR DNA-binding protein 43Homo sapiens (human)
interchromatin granuleTAR DNA-binding protein 43Homo sapiens (human)
nucleoplasmTAR DNA-binding protein 43Homo sapiens (human)
chromatinTAR DNA-binding protein 43Homo sapiens (human)
fibrillar centerInositol hexakisphosphate kinase 1Homo sapiens (human)
nucleoplasmInositol hexakisphosphate kinase 1Homo sapiens (human)
cytosolInositol hexakisphosphate kinase 1Homo sapiens (human)
nucleusInositol hexakisphosphate kinase 1Homo sapiens (human)
cytoplasmInositol hexakisphosphate kinase 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (82)

Assay IDTitleYearJournalArticle
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347112qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347119qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347129qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347121qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347109qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347111qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347424RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347114qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1347113qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347116qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347407qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347110qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for A673 cells)2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347118qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347126qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347123qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347122qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347425Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347128qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347127qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347115qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347124qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347125qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347117qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID1594779Protection against AfB1-induced toxicity in human HepG2 cells assessed as increase in live cell area at >12.5 uM measured after 48 hrs by calcein-AM/Hoechst 33342 staining based high-content imaging analysis relative to control2019Journal of natural products, 06-28, Volume: 82, Issue:6
Natural-Product-Inspired Compounds as Countermeasures against the Liver Carcinogen Aflatoxin B
AID390724Inhibition of HSL in Wistar rat isolated fat cells at 10 uM by spectrophotometric assay2008Journal of medicinal chemistry, Oct-23, Volume: 51, Issue:20
Combining ligand-based pharmacophore modeling, quantitative structure-activity relationship analysis and in silico screening for the discovery of new potent hormone sensitive lipase inhibitors.
AID763098Leishmanicidal activity against promastigote form of Leishmania amazonensis MHOM/BR/71973/M2269 after 72 hrs by cell counting2013Bioorganic & medicinal chemistry, Jun-01, Volume: 21, Issue:11
Synthesis and biological evaluation against Leishmania amazonensis of a series of alkyl-substituted benzophenones.
AID588211Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID1594776Protection against AfB1-induced toxicity in human HepG2 cells assessed as live cell area at 12.5 uM measured after 48 hrs by calcein-AM/Hoechst 33342 staining based high-content imaging analysis relative to control2019Journal of natural products, 06-28, Volume: 82, Issue:6
Natural-Product-Inspired Compounds as Countermeasures against the Liver Carcinogen Aflatoxin B
AID1178161In vitro photoprotection of the compound assessed as sun protection factor by Optometric 290S analyzer2014Bioorganic & medicinal chemistry, May-01, Volume: 22, Issue:9
Synthesis, antioxidant and photoprotection activities of hybrid derivatives useful to prevent skin cancer.
AID588212Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID390722Inhibition of HSL in Wistar rat isolated fat cells by spectrophotometric assay2008Journal of medicinal chemistry, Oct-23, Volume: 51, Issue:20
Combining ligand-based pharmacophore modeling, quantitative structure-activity relationship analysis and in silico screening for the discovery of new potent hormone sensitive lipase inhibitors.
AID977599Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID977602Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID763097Cytotoxicity against mouse peritoneal macrophages after 72 hrs by MTT assay2013Bioorganic & medicinal chemistry, Jun-01, Volume: 21, Issue:11
Synthesis and biological evaluation against Leishmania amazonensis of a series of alkyl-substituted benzophenones.
AID588213Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID1178163In vitro photoprotection of the compound assessed as UVA to UVB ratio by Optometric 290S analyzer2014Bioorganic & medicinal chemistry, May-01, Volume: 22, Issue:9
Synthesis, antioxidant and photoprotection activities of hybrid derivatives useful to prevent skin cancer.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID504749qHTS profiling for inhibitors of Plasmodium falciparum proliferation2011Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043
Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1159550Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening2015Nature cell biology, Nov, Volume: 17, Issue:11
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (468)

TimeframeStudies, This Drug (%)All Drugs %
pre-19909 (1.92)18.7374
1990's41 (8.76)18.2507
2000's86 (18.38)29.6817
2010's203 (43.38)24.3611
2020's129 (27.56)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 52.02

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index52.02 (24.57)
Research Supply Index6.23 (2.92)
Research Growth Index5.37 (4.65)
Search Engine Demand Index134.08 (26.88)
Search Engine Supply Index3.17 (0.95)

This Compound (52.02)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials15 (3.05%)5.53%
Reviews16 (3.26%)6.00%
Case Studies24 (4.89%)4.05%
Observational1 (0.20%)0.25%
Other435 (88.59%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Assessment of the Human Systemic Absorption of Sunscreen Ingredients [NCT03582215]Phase 172 participants (Actual)Interventional2018-07-18Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

TrialOutcome
NCT03582215 (7) [back to overview]Avobenzone Maximum Concentration
NCT03582215 (7) [back to overview]Ecamsule Maximum Concentration
NCT03582215 (7) [back to overview]Homosalate Maximum Concentration
NCT03582215 (7) [back to overview]Octinoxate Maximum Concentration
NCT03582215 (7) [back to overview]Octisalate Maximum Concentration
NCT03582215 (7) [back to overview]Octocrylene Maximum Concentration
NCT03582215 (7) [back to overview]Oxybenzone Maximum Concentration

Avobenzone Maximum Concentration

Maximum concentration (observed peak drug concentration) (Cmax) (NCT03582215)
Timeframe: 0, 0.5, 1, 1.5, 2, 4, 6, 8, 9, 10, 12, 14, 23, 28, 33, 47, 52, 57, 71, 73, 74, 76, 78, 81, 82, 84, 86, 95, 120, and 144 h for Part 1; same time points and 216, 312, and 480 h for Part 2

Interventionng/mL (Geometric Mean)
Part 1: Cream1.8
Part 1: Lotion4.3
Part 1: Spray 14.0
Part 1: Spray 23.4
Part 2: Lotion7.1
Part 2: Aerosol Spray3.5
Part 2: Nonaerosol Spray3.5
Part 2: Pump Spray3.3

[back to top]

Ecamsule Maximum Concentration

Maximum concentration (observed peak drug concentration) (Cmax) (NCT03582215)
Timeframe: 0, 0.5, 1, 1.5, 2, 4, 6, 8, 9, 10, 12, 14, 23, 28, 33, 47, 52, 57, 71, 73, 74, 76, 78, 81, 82, 84, 86, 95, 120, and 144 h for Part 1

Interventionng/mL (Geometric Mean)
Part 1: Cream1.5

[back to top]

Homosalate Maximum Concentration

Maximum concentration (observed peak drug concentration) (Cmax) (NCT03582215)
Timeframe: 0, 0.5, 1, 1.5, 2, 4, 6, 8, 9, 10, 12, 14, 23, 28, 33, 47, 52, 57, 71, 73, 74, 76, 78, 81, 82, 84, 86, 95, 120, 144, 216, 312, and 480 h for Part 2

Interventionng/mL (Geometric Mean)
Part 1: Spray 140.3
Part 2: Aerosol Spray23.1
Part 2: Nonaerosol Spray17.9
Part 2: Pump Spray13.9

[back to top]

Octinoxate Maximum Concentration

Maximum concentration (observed peak drug concentration) (Cmax) (NCT03582215)
Timeframe: 0, 0.5, 1, 1.5, 2, 4, 6, 8, 9, 10, 12, 14, 23, 28, 33, 47, 52, 57, 71, 73, 74, 76, 78, 81, 82, 84, 86, 95, 120, 144, 216, 312, and 480 h for Part 2

Interventionng/mL (Geometric Mean)
Part 2: Nonaerosol Spray7.9
Part 2: Pump Spray5.2

[back to top]

Octisalate Maximum Concentration

Maximum concentration (observed peak drug concentration) (Cmax) (NCT03582215)
Timeframe: 0, 0.5, 1, 1.5, 2, 4, 6, 8, 9, 10, 12, 14, 23, 28, 33, 47, 52, 57, 71, 73, 74, 76, 78, 81, 82, 84, 86, 95, 120, 144, 216, 312, and 480 h for Part 2

Interventionng/mL (Geometric Mean)
Part 1: Spray 110.0
Part 2: Aerosol Spray5.1
Part 2: Nonaerosol Spray5.8
Part 2: Pump Spray4.6

[back to top]

Octocrylene Maximum Concentration

Maximum concentration (observed peak drug concentration) (Cmax) (NCT03582215)
Timeframe: 0, 0.5, 1, 1.5, 2, 4, 6, 8, 9, 10, 12, 14, 23, 28, 33, 47, 52, 57, 71, 73, 74, 76, 78, 81, 82, 84, 86, 95, 120, and 144 h for Part 1; same time points and 216, 312, and 480 h for Part 2

Interventionng/mL (Geometric Mean)
Part 1: Cream5.7
Part 1: Lotion5.7
Part 1: Spray 12.9
Part 1: Spray 27.8
Part 2: Lotion7.8
Part 2: Aerosol Spray6.6
Part 2: Nonaerosol Spray6.6

[back to top]

Oxybenzone Maximum Concentration

Maximum concentration (observed peak drug concentration) (Cmax) (NCT03582215)
Timeframe: 0, 0.5, 1, 1.5, 2, 4, 6, 8, 9, 10, 12, 14, 23, 28, 33, 47, 52, 57, 71, 73, 74, 76, 78, 81, 82, 84, 86, 95, 120, and 144 h for Part 1; same time points and 216, 312, and 480 h for Part 2

Interventionng/mL (Geometric Mean)
Part 1: Lotion169.3
Part 1: Spray 1209.6
Part 1: Spray 2194.9
Part 2: Lotion258.1
Part 2: Aerosol Spray180.1

[back to top]